HLVX icon

HilleVax

1.39 USD
-0.06
4.14%
At close Apr 1, 4:00 PM EDT
After hours
1.43
+0.04
2.88%
1 day
-4.14%
5 days
-15.24%
1 month
-20.57%
3 months
-33.17%
6 months
-21.91%
Year to date
-33.17%
1 year
-91.27%
5 years
-92.72%
10 years
-92.72%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

113% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 15

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

21% more capital invested

Capital invested by funds: $73.5M [Q3] → $88.7M (+$15.2M) [Q4]

2.13% more ownership

Funds ownership: 83.87% [Q3] → 86.0% (+2.13%) [Q4]

4% less funds holding

Funds holding: 79 [Q3] → 76 (-3) [Q4]

23% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 13

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$2
44%
upside
Avg. target
$2
44%
upside
High target
$2
44%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
HC Wainwright & Co.
Matthew Caufield
33% 1-year accuracy
21 / 63 met price target
44%upside
$2
Neutral
Reiterated
31 Mar 2025

Financial journalist opinion

Neutral
GlobeNewsWire
4 days ago
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress
$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2024. Full Year 2024 Financial Results As of December 31, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling $171.4 million and $303.5 million, respectively.
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress
Positive
Zacks Investment Research
5 months ago
What Makes HilleVax (HLVX) a New Buy Stock
HilleVax (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes HilleVax (HLVX) a New Buy Stock
Neutral
Accesswire
7 months ago
HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)
NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)
Neutral
Accesswire
7 months ago
Levi & Korsinsky Investigates Possible Securities Fraud Violations by HilleVax, Inc. (HLVX)
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by HilleVax, Inc. (HLVX)
Neutral
Accesswire
7 months ago
Investors who lost money on HilleVax, Inc. should contact Levi & Korsinsky about an ongoing investigation - HLVX
NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
Investors who lost money on HilleVax, Inc. should contact Levi & Korsinsky about an ongoing investigation - HLVX
Neutral
Accesswire
7 months ago
HilleVax, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HLVX
NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
HilleVax, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HLVX
Neutral
Accesswire
7 months ago
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
Neutral
Accesswire
7 months ago
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
Neutral
Accesswire
7 months ago
HLVX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your HilleVax, Inc. investment
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
HLVX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your HilleVax, Inc. investment
Neutral
Accesswire
7 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ:HLVX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
Charts implemented using Lightweight Charts™